Chengdu Better Biopharmaceuticals

Chengdu Better Biopharmaceutical is a Chinese biopharmaceutical company and a subsidiary of Chengdu Better Pharmaceutical. Established in August 2020, the company serves as the primary scale manufacturing and development base for its parent company's biologics and peptide pipeline. Its lead program is BPR-201-I, a semaglutide biosimilar targeting the glucagon-like peptide 1 receptor (GLP1R) for the treatment of type 2 diabetes and obesity. The program has successfully completed Phase 3 clinical trials and has progressed to the NDA submission stage in China. The company operates advanced manufacturing facilities in Chengdu, Sichuan, designed to meet international GMP standards for the production of therapeutic peptides and other biologics.